Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma‐related non‐fatal serious adverse events · children with chronic asthma
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Any adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
It is very uncertain whether ciclesonide changes adverse events Number of patients with adverse events compared with fluticasone (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Duration of trials: 12 to 20 weeks · adults and adolescents with persistent asthma
The intervention probably leads to higher serious adverse events Duration of trials: 12 to 20 weeks (moderate certainty).
1 finding from 1 review
Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).
1 finding from 1 review
Treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) compared with usual care (low certainty).
1 finding from 1 review